Adaptimmune Wins Accelerated FDA Approval: A New Dawn in Cell Therapy for Solid Tumors

Revolutionizing Solid Tumor Treatment with Cell Therapy

Tecelra’s approval is a landmark achievement for the 16-year-old Adaptimmune, a company that has seen partnerships with major pharmaceutical giants such as GSK, Astellas, and Roche come and go. These partnerships were drawn by the potential of Adaptimmune’s unique engineered T-cell receptor (TCR) platform, which enables the engineering of T-cells to target and destroy various types of solid tumors. This platform is now validated with Tecelra’s approval, offering hope for more advancements in cell therapy for solid tumors.

The First Engineered T-Cell Therapy for Solid Tumors

Tecelra distinguishes itself as the first engineered T-cell therapy approved for solid tumors. John Lunger, Adaptimmune’s Chief Patient Supply Officer, explained, “It’s the first product where we use a lentiviral vector to insert our engineered T-cell receptor into the cell.” While Iovance’s Amtagvi (lifileucel), approved by the FDA in February for melanoma, was the first T-cell treatment for solid tumors, Tecelra’s engineering approach sets it apart. Unlike CAR-T cell therapies, which collect immune cells from a patient’s circulating blood, Amtagvi uses tumor-infiltrating lymphocytes (TILs) collected from a patient’s tumor.

A New Era in Cell Therapy for Solid Tumors

“Ninety percent of cancer is solid tumors,” Lunger noted. “The idea of a company like ourselves going after solid tumors using cells, we’re finally getting to that place where we’re demonstrating this can actually work.” Tecelra’s approval is a testament to this vision, with a list price of $727,000 for the one-time therapy. The addressable patient population in the U.S. is approximately 400 per year, making this a significant step forward in treating a rare but serious cancer.

FDA Approval and Market Impact

On August 2, the U.S. Food and Drug Administration announced the approval of Tecelra, a first-of-its-kind cell therapy for synovial sarcoma, a rare type of cancer affecting the soft tissues, predominantly in young people. This potentially life-threatening cancer previously had limited treatment options, including surgery, chemotherapy, and radiotherapy. Tecelra, administered as a one-time intravenous therapy, leverages the patient’s own immune response by modifying and using T-cells to fight the disease. Analysts note that Tecelra’s price is comparable to CAR-T cell therapies, which average around $500,000.

Clinical Trial Success and Future Potential

The FDA’s accelerated approval was based on promising data from a 44-patient study, where 43.2% of participants showed partial or complete response to Tecelra for an average duration of six months. Dr. Sandra D’Angelo, an oncologist at Memorial Sloan Kettering Cancer Center, remarked that therapies like Tecelra have the potential to treat other solid tumors due to their ability to target a broader range of tumor-causing proteins than currently approved therapies.

Market Reaction and Sales Projections

Despite this groundbreaking approval, Adaptimmune’s shares were trading 7% down in afternoon trading, although the stock has risen 46% this year. Guggenheim analyst Michael Schmidt estimates peak U.S. sales of Tecelra could reach $180 million, reflecting the therapy’s significant market potential.

Tecelra’s approval not only marks a major victory for Adaptimmune but also heralds a new era in the treatment of solid tumors with cell therapy, offering renewed hope for patients battling this challenging disease.

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services